Bone Marrow Transplantation Unit, Department of Hematology, Azienda Ospedaliera Policlinico-Vittorio Emanuele, Catania, Italy.
Exp Hematol. 2012 Jan;40(1):35-47.e2. doi: 10.1016/j.exphem.2011.10.002. Epub 2011 Oct 20.
A high number of CD34(+) cells in the peripheral blood during mobilization in patients with acute myeloid leukemia (AML) in complete remission (CR) is associated with a high relapse rate. The variability in chemoresistance of normal bone marrow precursors has been hypothesized as explanation for the variable CD34 mobilization in AML. In 37 patients with AML in CR, we determined the chemosensitivity of bone marrow clonogenic precursors to maphosphamide and etoposide, which was then correlated with the degree of CD34(+) mobilization. In an enlarged set of 49 patients, we also studied the importance of chemosensitivity of marrow precursors for disease-free survival and relapse incidence. Significant correlations were demonstrated between the peak number of CD34(+) cells and residual growth of colony-forming unit granulocyte-macrophage (CFU-GM) after maphosphamide (R = 0.550; p = 0.0003) and after etoposide (R = 0.793; p = 0.0003). It was possible to identify three groups of AML patients based on chemosensitivity. The mean CD34(+) peak was 33 × 10(6)/L in the hyperchemosensitive group, 141 × 10(6)/L in the normochemosensitive (p = 0.03), and 379 × 10(6)/L in the chemoresistant group (p = 0.002). Failed CD34(+) mobilization was observed in 72% of the hyperchemosensitive group, 23% of the normochemosensitive group, and 0% of the chemoresistant group (p = 0.001). Hyperchemosensitivity of CFU-GM, together with a low platelet count, were independent factors important in the failure of CD34(+) cell mobilization. A disease-free survival significantly inferior to that of all other patients was associated with chemoresistance of CFU-GM (log rank, p = 0.030) and with chemoresistance of burst-forming unit erythroid (BFU-E) (log rank, p = 0.033). Chemoresistance of CFU-GM (p = 0.048) and BFU-E (p = 0.017) was also associated with increase relapse incidence. Nonleukemic nature of these precursors was demonstrated studying minimal residual disease from single colony cells. In conclusion, we found that hyperchemosensitivity of normal nonleukemic CFU-GM is associated with a high risk of CD34(+) cell mobilization failure, while a chemoresistant pattern in CFU-GM and BFU-E is associated with poor disease-free survival and increased cumulative incidence of relapse.
在完全缓解(CR)的急性髓系白血病(AML)患者的动员期间外周血中 CD34(+)细胞数量高与复发率高有关。正常骨髓前体的化疗耐药性的可变性已被假设为 AML 中 CD34 动员的可变原因。在 37 例 AML-CR 患者中,我们确定了骨髓克隆形成前体对氨甲喋呤和依托泊苷的化疗敏感性,然后将其与 CD34(+)动员的程度相关联。在一组 49 例患者中,我们还研究了骨髓前体的化疗敏感性对无病生存和复发发生率的重要性。CD34(+)细胞的峰值数量与氨甲喋呤后集落形成单位粒细胞-巨噬细胞(CFU-GM)的残留生长(R = 0.550;p = 0.0003)和依托泊苷后(R = 0.793;p = 0.0003)之间存在显著相关性。可以根据化疗敏感性将 AML 患者分为三组。超化疗敏感组的平均 CD34(+)峰值为 33 × 10(6)/L,正常化疗敏感组为 141 × 10(6)/L(p = 0.03),化疗耐药组为 379 × 10(6)/L(p = 0.002)。超化疗敏感组中 72%的患者出现 CD34(+)动员失败,正常化疗敏感组中 23%的患者出现 CD34(+)动员失败,而化疗耐药组中 0%的患者出现 CD34(+)动员失败(p = 0.001)。CFU-GM 的超化疗敏感性以及血小板计数低是 CD34(+)细胞动员失败的重要独立因素。与所有其他患者相比,无病生存显著较差与 CFU-GM 的化疗耐药性(对数秩,p = 0.030)和爆式形成单位红细胞(BFU-E)的化疗耐药性(对数秩,p = 0.033)相关。CFU-GM(p = 0.048)和 BFU-E(p = 0.017)的化疗耐药性也与复发发生率增加相关。通过对单个集落细胞的微小残留疾病进行研究,证明了这些前体的非白血病性质。总之,我们发现正常非白血病 CFU-GM 的超化疗敏感性与 CD34(+)细胞动员失败的高风险相关,而 CFU-GM 和 BFU-E 的化疗耐药性与无病生存不良和累积复发率增加相关。